Latest Breaking News On - இயற்கை மதிப்புரைகள் நோய் ப்ரைமர்ஸ் - Page 1 : vimarsana.com
Ipsen and Exicure, Inc : Ipsen and Exicure Enter Into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Paediatric Allergic Rhinitis: Common but undiagnosed in Ireland and UK
imt.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imt.ie Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
MARLBOROUGH, Mass., March 3, 2021 /PRNewswire/ Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement with an affiliate of Baring Private Equity Asia (BPEA) to acquire the global surgical business of Lumenis LTD., a privately-held company that develops and commercializes energy-based medical solutions, for an upfront cash payment of $1.07 billion, subject to closing adjustments. BPEA will retain ownership of the Lumenis global aesthetics and ophthalmology businesses. With 2021 net sales anticipated to be approximately $200 million, the Lumenis surgical business includes premier laser systems, fibers and accessories used for urology and otolaryngology procedures. Foundational to its urology portfolio is the proprietary MOSES™ technology, which has demonstrated differentiated clinical outcomes and efficiency in the management of patients with kidney stones.
(1)
Adds to Portfolio of 40 Patents for Catheter-Based Technology That Leverages Power of Body s Natural Fluid Removal Process
WhiteSwell, a company pioneering new ways to treat acute decompensated heart failure, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the company a new patent for treating ADHF patients with a catheter technology designed to stimulate lymphatic drainage using a novel impeller pump combined with restrictors.
This patent grant, which is WhiteSwell s third this year, adds to its rapidly expanding U.S. patent portfolio covering a set of devices that leverage the lymphatic system s remarkable innate drainage properties for fluid-overloaded ADHF patients. WhiteSwell has received 10 patent grants from the U.S. PTO in the last two years, and has a U.S. portfolio of over 40 patents granted or pending.